Guardant Health (NASDAQ:GH) Director Steve Krognes Sells 6,674 Shares

Guardant Health, Inc. (NASDAQ:GH) Director Steve Krognes sold 6,674 shares of the company’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $175.74, for a total transaction of $1,172,888.76. Following the completion of the sale, the director owned 7,906 shares of the company’s stock, valued at approximately $1,389,400.44. This represents a 45.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Guardant Health Trading Up 4.7%

Shares of Guardant Health stock opened at $183.10 on Friday. The stock’s fifty day simple moving average is $160.71 and its 200 day simple moving average is $127.10. The company has a market capitalization of $24.57 billion, a PE ratio of -52.46 and a beta of 1.57. Guardant Health, Inc. has a 12 month low of $55.38 and a 12 month high of $183.51.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.34. The business had revenue of $334.98 million during the quarter, compared to analyst estimates of $314.23 million. During the same period in the previous year, the firm posted ($0.44) earnings per share. The firm’s revenue was up 44.3% on a year-over-year basis. Analysts predict that Guardant Health, Inc. will post -2.98 EPS for the current fiscal year.

Analysts Set New Price Targets

GH has been the subject of a number of research reports. Guggenheim increased their target price on Guardant Health from $160.00 to $190.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Mizuho lifted their price target on shares of Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a report on Friday, July 17th. Sanford C. Bernstein reissued an “outperform” rating and set a $210.00 price objective on shares of Guardant Health in a research report on Thursday, September 10th. Finally, Barclays raised their price objective on shares of Guardant Health from $150.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Guardant Health presently has a consensus rating of “Moderate Buy” and an average target price of $188.12.

Key Guardant Health News

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Guardant Health was described as nearing a technical buy point as its sales outlook brightened, supporting investor confidence in continued revenue growth. Guardant Health Nears Buy Point As Sales Outlook Brightens
• Positive Sentiment: A comparison of second-quarter testing and diagnostics companies highlighted Guardant Health’s strong performance. The company’s revenue rose 44.3% year over year to approximately $335 million and exceeded analyst expectations, while its quarterly loss was narrower than forecast. Testing & diagnostics services stocks Q2 results: Benchmarking Guardant Health
• Positive Sentiment: The stock reached a new one-year high, reflecting strong momentum and investor demand following its recent rally. The move could attract additional momentum-oriented buyers, though it also raises the risk of profit-taking. Guardant Health Reaches New 1-Year High – What’s Next?
• Neutral Sentiment: Director Musa Tariq sold 116 shares for about $20,300, reducing his position by 1%. The transaction was executed under a pre-arranged Rule 10b5-1 plan, making it a limited and less concerning signal. SEC Form 4 filing
• Negative Sentiment: Several insiders reported sales: Director Alex M. Azar II sold 826 shares for approximately $144,550, Director Steve Krognes sold 6,674 shares for roughly $1.17 million, and CTO Darya Chudova sold 7,738 shares for about $1.38 million. The transactions reduced their holdings substantially and could raise profit-taking concerns, although the sales were disclosed through SEC filings and some were conducted under pre-arranged plans. Insider sale SEC filing

Institutional Investors Weigh In On Guardant Health

A number of hedge funds and other institutional investors have recently bought and sold shares of GH. Orbimed Advisors LLC acquired a new stake in shares of Guardant Health in the 1st quarter valued at approximately $40,199,000. GSA Capital Partners LLP acquired a new position in Guardant Health during the second quarter worth $1,772,000. Ninepoint Partners LP bought a new stake in Guardant Health during the second quarter worth $2,853,000. SWS Partners bought a new stake in Guardant Health during the second quarter worth $11,190,000. Finally, Eagle Health Investments LP acquired a new stake in Guardant Health in the second quarter valued at $45,112,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients over time. Its liquid biopsy technologies analyze tumor-related signals in blood, reducing the need for tissue biopsies in certain clinical and research settings.

The company’s products include Guardant360 tests, which profile advanced cancers and can help identify potentially actionable genomic alterations; Guardant Reveal, which is used to assess residual disease and recurrence risk; and Guardant Shield, a blood-based screening test for colorectal cancer.